Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Velban Clear all
Terminated Phase 2 Interventional Results available

Metronomic Therapy in Patients With Metastatic Melanoma

NCT01542255
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
vinblastine, Cyclophosphamide, dacarbazine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 7, 2026, 9:42 AM EDT
Terminated Phase 3 Interventional Results available

4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00005047
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2014
U.S. locations
73
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

NCT01476410
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine, quality-of-life assessment, DNA analysis, RNA analysis, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis, immunohistochemistry staining method, polymorphism analysis
Drug · Procedure · Genetic + 2 more
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Terminated Phase 3 Interventional

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

NCT00005090
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis

NCT00215046
View directory record Official record
Conditions
Intraluminal Pulmonary Vein Stenosis
Interventions
Vinblastine, Methotrexate
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 7, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

NCT05253495
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy
Drug · Radiation
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 39 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Gainsville, Florida • Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

NCT00352495
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Interventions
carboplatin, vinblastine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 7, 2026, 9:42 AM EDT
Active, not recruiting Phase 2 Interventional

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

NCT05404945
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Pembrolizumab, Doxorubicin, Vinblastine, Dacarbazine, Brentuximab vedotin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
60 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Not listed Phase 2 Interventional

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

NCT02840409
View directory record Official record
Conditions
Low Grade Glioma
Interventions
Vinblastine, Bevacizumab
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
6 Months to 18 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 7, 2026, 9:42 AM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Drug Screening Using IMD in Bladder Cancer

NCT06204614
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, Enfortumab, Sacituzumab
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

NCT01132807
View directory record Official record
Conditions
Lymphoma
Interventions
Bleomycin Sulfate, Doxorubicin Hydrochloride, Procarbazine Hydrochloride, Vinblastine Sulfate, Dacarbazine, Cyclophosphamide, Etoposide phosphate, prednisone, Radiation Therapy, Fludeoxyglucose F-18, computed tomography, Positron Emission Tomography
Biological · Drug · Radiation + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 60 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
95
States / cities
Tucson, Arizona • Duarte, California • New Haven, Connecticut + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 7, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

NCT00722865
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Avastin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 7, 2026, 9:42 AM EDT
Active, not recruiting Phase 2 Interventional

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

NCT03233347
View directory record Official record
Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Dacarbazine, Doxorubicin, Laboratory Biomarker Analysis, Nivolumab, Vinblastine
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Duarte, California • Rochester, Minnesota • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

NCT04383743
View directory record Official record
Conditions
Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
Interventions
Cisplatin, Doxorubicin, Methotrexate, Pegfilgrastim, Pembrolizumab, Radical Cystectomy, Vinblastine Sulfate
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 3 Interventional

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

NCT00002855
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium, Flutamide, Ketoconazole, Nilutamide, Therapeutic Hydrocortisone, Vinblastine, Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 7, 2026, 9:42 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

NCT02205762
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
Drug · Procedure · Biological
Lead sponsor
North American Consortium for Histiocytosis
Other
Eligibility
Up to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

NCT02412670
View directory record Official record
Conditions
High Grade Upper Tract Urothelial Carcinoma
Interventions
Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim, Nephroureterectomy
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

NCT01578967
View directory record Official record
Conditions
Hodgkin Lymphoma, Adult
Interventions
Brentuximab vedotin, ABVD
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
6
States / cities
Duarte, California • Rochester, Minnesota • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

NCT00004010
View directory record Official record
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, ABVD regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
37
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Sep 7, 2026, 9:42 AM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 7, 2026, 9:42 AM EDT
Terminated Phase 3 Interventional

R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

NCT00992030
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Rituximab, Involved field irradiation
Drug · Radiation
Lead sponsor
Fondazione Michelangelo
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

NCT00276757
View directory record Official record
Conditions
Childhood Langerhans Cell Histiocytosis
Interventions
leucovorin calcium, methotrexate, prednisolone, vinblastine sulfate
Drug
Lead sponsor
Histiocyte Society
Other
Eligibility
Up to 17 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
4
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 7, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

NCT02710734
View directory record Official record
Conditions
Urothelial Carcinoma of the Bladder
Interventions
Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Intensity modulated radiation therapy (IMRT), Transurethral Resection of Bladder tumor, 5-FU, Mitomycin C
Drug · Radiation · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 7, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

NCT07551583
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 9:42 AM EDT